Physician profile
Ramses Ramirez
NPI 1427551274
$5,366.05
in general payments reported to CMS, 2019-2025
21 companies · $2,450 in 2025
The $2,450 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $959 · 2023: $881 · 2024: $387 · 2025: $2,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Travel and Lodging: $1,328 · Grant: $200 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.13 |
| Travel and Lodging | $1,328.47 |
| Grant | $200.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,214.64 | 2021-2023 | Nuzyra |
| Stryker Corporation | $814.05 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Philips North America LLC | $713.61 | 2025 | Igt Devices Undivided |
| Abbvie INC. | $685.20 | 2021-2023 | |
| Shockwave Medical, INC | $313.58 | 2025 | |
| Medtronic, INC. | $260.55 | 2024-2025 | Corevalve Evolut R, Symplicity G3, Mycarelink |
| Ferring Pharmaceuticals INC. | $254.05 | 2023 | Rebyota |
| Cook Incorporated | $200.00 | 2025 | |
| Pfizer INC. | $165.12 | 2024-2025 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Veklury |
| Insmed, INC. | $124.53 | 2022 | |
| La Jolla Pharmaceutical Company | $94.29 | 2022 | |
| Abiomed | $84.59 | 2025 | |
| Amgen INC. | $51.25 | 2025 | Repatha |
| W. L. Gore & Associates, INC. | $50.00 | 2025 | Gore-Tex Vascular Graft |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.83 | 2024-2025 | Merlin@Home, Cardiomems |
| Melinta Therapeutics, LLC | $43.74 | 2024 | Rezzayo |
| Boston Scientific Corporation | $37.35 | 2024 | Ingevity+ |
| Kestra Medical Technology Services, INC. | $35.14 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $31.73 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.80 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramses Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.